hale & tempest global generics marketplace dr. brian w tempest [email protected] uk...
TRANSCRIPT
Hale & Tempest
Global Generics Marketplace
Dr. Brian W Tempest
www.briantempest.com
UK
18,19,20 March 2014
Hale & Tempest
Hale & Tempest
1. Global Healthcare
2. Big Pharma
3.Global Generic Marketplace
4.Global Generic Companies
5.Indian Generic Marketplace
6.Indian Generic Companies
7. Country Generic Markets
8. Biosimilars
9. Generic Distribution
10. Over The Counter Consumer Medines
11. Contract Manufacturers
Hale & Tempest
Global Healthcare & Big Pharma
Chesapeake
Dr. Brian W Tempest
www.briantempest.com
UK
March 2014
Hale & Tempest
1. Global Healthcare
Hale & Tempest
There are only a few certain thingsSource: T Stevenson, Fidelity Worldwide Investment Director, S Telegraph April 21 2013
•Populations growth
•Ageing
•Expansion of the World’s Middle Classes
•Increasing demand for healthcare is as close to given as investors can hope for
Hale & Tempest
Rise of the Middle Classes source: Frost & Sullivan
Hale & Tempest
Aging in OECDsource: EGA
Hale & Tempest
Global Healthcare Growth by Region Source: Sunday Telegraph April 21 2013
Hale & Tempest
Healthcare costs versus GDP & Wages
Hale & Tempest
Public Health as % of GDPSource: UNDP 15 October 2012
Cuba 9.7% USA 9.5% France 9.3% UK 8.1%
Brazil 4.2% RSA 3.9% Russia 3.2% China 2.7% India 1.2%
Hale & Tempest
Military vs Healthsource: FT 24February 2014
Hale & Tempest
Public Health Reform Everywhere
Hale & Tempest
OECD Healthcare Expenditure Growth
source: Annalisa Belloni OECD at EGA Conference 13 June 2013
Hale & Tempest
Everybody Concerned about Health Costs
Hale & Tempest
Healthcare as % of Government Spend
source: WHO, Jefferies
Hale & Tempest
Public & Private Healthcare as % of GDP
source: WHO, India is <4%
Hale & Tempest
How Easy to Start a Business in EMs
source: Mint 13 October 2013
Hale & Tempest
Number of Companies with Active R&D Pipelines source: Citeline Pharma R&D Annual Review 2013
Hale & Tempest
Worldwide R&D Spend
source: Evaluate Pharma 23 June 2013
Hale & Tempest
R&D Spending by Countrysource: Economist March 22 2014
Hale & Tempest
Rise of Asia R&Dsource: Economist March 22 2014
Hale & Tempest
Emerging Markets Pharma Markets, $b
Source: Citi Research August 2013
Hale & Tempest
Value of EM Bourses - limited availabilitysource: January 18 2014 Economist
Hale & Tempest
OECD vs. BRICS
source: FT 9 October 2013
Hale & Tempest
Emerging Marketssource: Business India December 8 2013
Hale & Tempest
The Need for Universal Healthcare
source: ET 2 Aug 2013
Hale & Tempest
Healthcare will explode further in Asia
Hale & Tempest
Asian Healthcare Expenditure $b
source: EIU for countries PRC, HK, I, Ind, M, P, Si, SK, Tw , Th, V
Hale & Tempest
Pharmaceutical Imports into USA source: Chemistry World July 2012
Hale & Tempest
Cipla - Washington Post Ad
Hale & Tempest
Sovaldi (sofosbuvir) for Hepatitis CSource: Pharmatimes February 7 2014
•In USA Gilead Sciences charges Sovaldi at $1000 a day for a 12 week course -$84,000
•The cost of manufacture of the same 12 week course is $68 to $136 according to MSF generating a gross profit over 99%
•In India and other emerging markets Gilead plans to charge $2,000 for a 24 week course leading to a gross profit of 86%
Hale & Tempest
Evolving Emerging Markets IP PolicySource: Leaky Pharma 27 Jan 2014
•“This is genocide, This can sentence South Africans to death” – RSA Health Minister (Motsoaldi)
•1998 Big Pharma, Merck vs Mandela, PR disaster
•Enhanced Therapeutic Efficacy vs Incremental Efficacy
•2014 Merck, PhRMA, Lobbyist PAE vs RSA IP policy
•OECD growth +1-4% vs Emerging Markets at +10-13%
•WHO Executive Board – “we cannot be sidetracked from our course of action of defending public health and the right to life” (DG Precious Matsoso)
Hale & Tempest
Davos 2014 -Ten Global Risks of Highest Concern source: Davos 2014
Hale & Tempest
Aid by Countrysource: Economist 12 April 2014
Hale & Tempest
2. Big Pharma
Hale & Tempest
Big Pharma Business Model Broken source: Pharmatimes World News April 2012
Hale & Tempest
Pharma in Crisis Source: Pharmatimes February 2013
Hale & Tempest
A Slide from a UK Headhunter
Hale & Tempest
Top 10 Marketing Settlements Source: Fiercepharma 26 June 2012
GSK $3b 2012 Pfizer $2.3b 2009 J&J $2.2b 2012 Abbott 1.6b 2012 Lilly $1.4b 2009 Merck $1.0b 2011 Serono $0.7b 2005 Perdue $0.7b 2007 Allergan $0.6b 2010
Hale & Tempest
A Pfizer Decade of Bribery source: FT August 7 2012
Hale & Tempest
The Biggest Healthcare Fraud in HistorySource: Daily Mail 3 July 2012
Hale & Tempest
China Bribery Investigations
source: Jefferies November 2013
Hale & Tempest
Emerging Markets are Not so Easy
Hale & Tempest
Will Big Pharma Change?
Hale & Tempest
Or be like Popeye the sailor man
“I Yam what I Yam what I Yam”
Hale & Tempest
The Strategic Changes by Big PharmaSource: FT December 5 2012, Franz Humer, Roche Chairman
•Possible to cut 30-50% off development costs via CT efficiencies
•Shift from product focus to patient focus using diagnostic tools
• In Europe there isn’t one Government or politician interested in the health of the Industry
•USA & Latin American countries open to rewarding innovation
•Industry has to change fundamentally how it manages costs
•Leaner headquarters & smaller central functions •Division of the industry into 2 parts
• A Innovative businesses able to charge a premium price
• B Large scale manufacturers who can compete on cost
Hale & Tempest
Divestment & Spin Off StrategiesSource: IPA 2013
•Novartis - Blood Diagnostics, Animal Health, OTC, Vaccines•Bayer - Bayer Material Sciences likely
•Abbott - Abbvie (pharma assets)
•Pfizer - Nutrition, Zoetis Animal Health
•Merck - separate growth businesses from value businesses, Consumer OTC
•GSK - tail products to Aspen, drinks brands
•J&J - Diagnostics
Hale & Tempest
2013 The Year of 8 Blockbusterssource: Evaluate March 2014
Hale & Tempest
2013 the 8 Blockbusterssource: Evaluate March 2014
Hale & Tempest
Big Pharma Top 10 by 2012 Sales
Source: FiercePharma 29 November 2013
Hale & Tempest
Top 10 Medtech Companies
source: Evaluate Pharma, 23 September 2013
Hale & Tempest
Pharma & Medtech Global Markets
source: Evaluate 23 September 2013
Hale & Tempest
Global Pharma Salessource: Evaluate April 2014
Hale & Tempest
Sales at Risksource: Evaluate April 2014
Hale & Tempest
Global Pharma sales lost & sales gainedsource: Evaluate March 2014
Hale & Tempest
Biggest Expected Launches of 2014source: EvaluatePharma
Hale & Tempest
Strength of Local Companiessource: IMS May 2012
Hale & Tempest
Big Pharma Top Risers & Fallers in 2013source: Evaluate March 2014
Hale & Tempest
2013 a healthy year for Pharmasource: Evaluate March 2014
